MacroGenics-Logo-(transparent-background).png
MacroGenics Provides Update on Corporate Progress and 2023 Financial Results
March 07, 2024 16:01 ET | MacroGenics, Inc.
Presentation of preliminary data from TAMARACK Phase 2 study of vobra duo in mCRPC patients expected at ASCO 2024Initiation of Phase 1 study of MGC026, MacroGenics' first topoisomerase I...
MacroGenics-Logo-(transparent-background).png
MacroGenics to Participate in Upcoming Investor Conferences
March 01, 2024 17:48 ET | MacroGenics, Inc.
ROCKVILLE, MD, March 01, 2024 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative monoclonal...
MacroGenics-Logo-(transparent-background).png
MacroGenics Announces Date of Fourth Quarter 2023 Financial Results Conference Call
February 27, 2024 17:45 ET | MacroGenics, Inc.
ROCKVILLE, MD, Feb. 27, 2024 (GLOBE NEWSWIRE) --  MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative antibody-based...
MacroGenics-Logo-(transparent-background).png
MacroGenics to Participate in Upcoming Investor Conference
February 02, 2024 16:30 ET | MacroGenics, Inc.
ROCKVILLE, MD, Feb. 02, 2024 (GLOBE NEWSWIRE) --  MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative monoclonal...
MacroGenics-Logo-(transparent-background).png
MacroGenics to Participate in Upcoming Investor Conference
January 08, 2024 16:30 ET | MacroGenics, Inc.
ROCKVILLE, MD, Jan. 08, 2024 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative monoclonal...
MacroGenics-Logo-(transparent-background).png
MacroGenics Provides Update on Corporate Progress and Third Quarter 2023 Financial Results
November 06, 2023 16:01 ET | MacroGenics, Inc.
Completed enrollment of TAMARACK Phase 2 study of vobra duo ahead of scheduleInitiated LORIKEET Phase 2 study of lorigerlimab Submitted IND for MGC026, a topoisomerase inhibitor-based ADC Conference...
MacroGenics-Logo-(transparent-background).png
MacroGenics to Participate in Upcoming Investor Conferences
November 02, 2023 16:30 ET | MacroGenics, Inc.
ROCKVILLE, MD, Nov. 02, 2023 (GLOBE NEWSWIRE) --  MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative antibody-based...
MacroGenics-Logo-(transparent-background).png
MacroGenics Announces Date of Third Quarter 2023 Financial Results Conference Call
October 31, 2023 16:30 ET | MacroGenics, Inc.
ROCKVILLE, MD, Oct. 31, 2023 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative antibody-based...
MacroGenics-Logo-(transparent-background).png
MacroGenics Announces Achievement of $15 Million Milestone Related to Gilead’s Nomination of a Bispecific Research Program
September 05, 2023 07:00 ET | MacroGenics, Inc.
ROCKVILLE, MD, Sept. 05, 2023 (GLOBE NEWSWIRE) --  MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative antibody-based...
MacroGenics-Logo-(transparent-background).png
MacroGenics to Participate in Upcoming Investor Conferences
August 31, 2023 16:30 ET | MacroGenics, Inc.
ROCKVILLE, MD, Aug. 31, 2023 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative antibody-based...